A Phase II Study of MK-2206 in the Treatment of Recurrent High-Grade Serous Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Latest Information Update: 08 Nov 2021
At a glance
- Drugs MK 2206 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 29 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 May 2013 Planned number of patients changed from 44 to 29 as reported by ClinicalTrials.gov.
- 15 May 2013 Planned end date changed from 1 Mar 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov.